June 11, 2025 8:39am

I am Not sure if current upside can be safely maintained or preserved for distribution

Econs could use larger percentages to kill upside momentum that could cause share pricing to spoil.

 

BREAKING: Inflation in May was lower than anticipated. The consumer price index rose 0.1% in May from April, less than the 0.2% estimate from economists. Core CPI, which strips out volatile food and energy prices, also increased 0.1%, less than expected.

No false narratives or fake news; to read insights and analysis on the latest sector action, check out Pre-Open Brief

Never leave an investor uninformed!

 

Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.

“I also hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”

My interpretation of the morning’s numbers is written to be informative; it’s built on what happened to make “it” happen today!

 

Tuesday’s night’s … RegMed Investors (RMi) Closing Bell: got it up … https://www.regmedinvestors.com/articles/13953

RegMed Investors (RMi) Research Note: Harvard Apparatus GT (OTCQB): PONZI Scheme at its best or was convicted Bernie Madoff also resurrected … https://www.regmedinvestors.com/articles/13812

 

Wednesday: The pre-open Dow futures are UP +0.10% or (+39 points), the S&P futures are UP +0.21% or (+12 points) and the Nasdaq futures are UP +0.30% or (+66 points)

  • Stock futures slipped and then flipped up after CPI "numbers" on Wednesday. 6/11.
  • European stocks eke out gain,
  • Asia-Pacific markets climbed Wednesday

 

Henry’omics: We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies

  • Tuesday: The Dow closed UP +105.11 points or +0.25%, the S&P closed UP +32.93 points or +0.55% while the Nasdaq closed UP +123.75 points or +0.63%
  • Monday: The Dow closed DOWN -1.11 points or -0.00%, the S&P closed UP +5.52 points or +0.09% while the Nasdaq closed UP +61.28 points or +0.30%
  • Friday: The Dow closed UP +443.13 points or +1.05%, the S&P closed UP +61.06 points or +1.03% while the Nasdaq closed UP +231.50 points or +1.20%

Economic Data Docket:  Consumer price index (CPI)                       

  • Economists call for a 0.2% month-over-month increase, while headline CPI is anticipated to have grown 2.4% from 12 months earlier. A hot report could spook investors who are already on edge over inflationary pressures.

 

Q2 – June – 1 neutral and 6 positive closes

  • May – 1 market holiday, 10 negative and 11 positive closes
  • Q2 - April – 10 negative and 11 positive closes

 

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.  A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

  • Better part of valor to not lead any investor to temptation; yet again, I am passing on forecasting the daily indications as to expectation while the aftermarket blanked while the pre-open waits for the …  econs, it is still a mix of ups, downs and just uncertainty

 

The BOTTOM LINE: Not a clairvoyant, there are session that are just a flip-of-the-coin

As I ruminated, is the cell and gene therapy sector, a bit over-extended?

Note about timing …

  • After filing to go public in the cautious optimism around the J.P. Morgan Healthcare Conference in January, a Odyssey Therapeutics Inc., a Boston biotech is now pulling the plug on its IPO plans.
  • Filed new paperwork with the SEC on Monday requesting to withdraw its S-1 form, which kicks off the IPO process. The Boston biotech said it was seeking to withdraw its registration statement because it “determined that it is not in the best interests of the Company to conduct the proposed offering at this time.”
  • Only one Massachusetts biotech has eked out an IPO so far this year. Sionna Therapeutics Inc., which announced its intention to go public around the same time as Odyssey, held its IPO in February. The Waltham biotech raised $191 million by selling 10.6 million shares for $18 each. <Boston Business Journal>

Could sector share pricing currently be 5–10% too high and what weaker growth could mean for Fed’s rate cuts.

June ’25: understand the “flow” of markets, the cell and gene therapy sector and economic karma…

  • 6/10 - Tuesday closed positive with 17 positive, 15 negative and 3 flats
  • 6/9 - Monday closed neutral with 16 positive, 16 negative and 3 flats
  • 6/6 – Friday negative with 4 positive, 28 negative and 3 flats
  • 6/5 - Thursday closed positive with 16 positive, 15 negative and 4 flats
  • 6/4 – Wednesday closed positive with 18 positive, 13 negative and 4 flats
  • 6/3 - Tuesday closed positive with 24 positive, 8 negative and 3 flats
  • 6/2 - Monday closed positive with 25 positive, 7 negative and 3 flats

 

VIP … DATA, investors will receive the latest U.S. jobs-market update from the Labor Department.

 

Reiterating, “There are always some big ifs, especially given some of the headlines that could emanate after a past few months of news flatulence.

  • Still a believer after I wrote, about June… “Get back-in and re-test the sector waters after May’s cell and gene therapy sector ‘s month alternations, nibble!  Some believe in a “June Swoon;” however, June will be no better or worse than any other month. Although, I consider the so-called summer rally after the peripatetic or wandering.”

As always, brace ourself for more volatility, economics and their down trending affect?

Welcome to my world of defining the “grey’ in our universe!

  • The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities.

I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed.